Clinical trial
A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase…
NCT00001683 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00001683 |
|---|---|
| Title | A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer |
| Official title | A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma, Melanoma, Neoplasm Metastasis, Renal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | COL-3 |
| Enrollment | 35 |
| Start date | Oct 1, 1997 |
| Completion | Aug 1, 2003 |
| First posted | Nov 4, 1999 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: